Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Aranzazu Fernandez-MartinezIan E KropDavid W HillmanMei-Yin C PolleyJoel S ParkerLucas HuebnerKatherine A HoadleyJonathan ShepherdSara M TolaneyNorah L HenryChau DangLyndsay HarrisDonald A BerryOlwen HahnClifford A HudisEric P WinerAnn H PartridgeCharles M PerouLisa A CareyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.
Keyphrases
- positive breast cancer
- phase iii
- open label
- locally advanced
- phase ii
- clinical trial
- rectal cancer
- neoadjuvant chemotherapy
- study protocol
- lymph node
- epidermal growth factor receptor
- single cell
- squamous cell carcinoma
- genome wide
- metastatic breast cancer
- free survival
- radiation therapy
- randomized controlled trial
- gene expression
- real time pcr
- tyrosine kinase